AMPH - CIK 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $156.12M | $213.39M | $183.50M | $89.18M | $97.99M | $57.27M |
| Capital expenditure | $34.88M | $41.04M | $38.17M | $24.03M | $27.46M | $33.85M |
| Investing cash flow | -$70.33M | -$124.93M | -$649.12M | -$32.78M | -$28.67M | -$36.41M |
| Dividends paid | - | - | - | - | - |
Amphastar Pharmaceuticals, Inc. reported operating cash flow of $156.12M for fiscal year 2025. That is down 26.8% from $213.39M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $38.56M (FY 2016) to $156.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $75.59M | $85.46M | $58.14M | $39.91M | $28.87M | $24.43M |
| Financing cash flow | -$67.42M | -$80.95M | $454.09M | -$26.44M | -$37.02M | -$2.25M |